Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Tata Memorial Centre is the lead sponsor of 42 current clinical trials in our India register. 35 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Chlorophyllin, Sodium Copper Complex, Cisplatin and Bevacizumab. The most-studied condition is Glioma.

ClinicalTrials.gov trials by status

Recruiting3583%
Not yet open25%
Active, closed512%

Trials by phase

Not applicable1331%
Phase 21126%
Observational1024%
Phase 3512%
Phase 2/325%
Phase 1/212%

Clinical trials sponsored by Tata Memorial Centre

42 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors NCT07236840 · CNS Tumor, Artificial Intelligence (AI), Glioma	Observational	Recruiting	2026-02	India
IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer NCT06630793 · Malignant Neoplasm of Anal Canal	Not applicable	Recruiting	2025-03	India
Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial NCT06818682 · Prostate Carcinoma	Phase 2	Recruiting	2025-02	India
Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT) NCT07338526 · Brain Tumor, Pediatric	Not applicable	Recruiting	2025-08	India
BIO-SHORT: Hypofractionated RT for Poor-Prognosis GBM NCT07338539 · Glioma	Not applicable	Recruiting	2025-11	India
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients NCT07062263 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, HER2-positive Cancer, Advanced Cancer Drug: Trastuzumab	Phase 3	Recruiting	2023-07	India
Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer NCT02992574 · ClinicalTrials.gov ↗ · Breastcancer	Not applicable	Recruiting	2016-05	India
Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients NCT07724873 · ClinicalTrials.gov ↗ · Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy	Phase 1/2	Recruiting	2025-01	India
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers NCT07337850 · ClinicalTrials.gov ↗ · Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)	Observational	Recruiting	2024-09	India
Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease. NCT07708987 · ClinicalTrials.gov ↗ · Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory	Phase 2	Recruiting	2023-09	India
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow NCT06492486 · ClinicalTrials.gov ↗ · Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy	Phase 2	Recruiting	2026-07	India
Tracing Brain Tumors Through Deep Time NCT06381531 · ClinicalTrials.gov ↗ · Brain Tumor, Oncology	Observational	Recruiting	2025-01	India
Assessment of the Breast Cosmesis Using Deep Neural Networks: an Exploratory Study (ABCD) NCT05450016 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2021-10	India
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study NCT05857631 · ClinicalTrials.gov ↗ · Cervical Cancer, Endometrial Cancer Drug: Cisplatin	Not applicable	Recruiting	2023-05	India
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant NCT07709195 · ClinicalTrials.gov ↗ · Oral Mucositis, Total Body Irradiation, Hematological Malignancies	Phase 2	Recruiting	2024-10	India
Artificial Intelligence in CNS Radiation Oncology NCT06036394 · ClinicalTrials.gov ↗ · CNS Tumor	Observational	Recruiting	2023-09	India
Short Versus Long-term Levetiracetam in Brain Tumors NCT06442748 · ClinicalTrials.gov ↗ · Seizures, Brain Tumors, Antiepileptics Drug: Levetiracetam	Phase 3	Recruiting	2024-07	India
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients NCT07709013 · ClinicalTrials.gov ↗ · Hematologic Malignancies Drug: Leflunomide	Phase 2	Recruiting	2024-10	India
Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia NCT06058572 · ClinicalTrials.gov ↗ · Acute Leukemia	Phase 2	Recruiting	2024-08	India
Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI NCT06275035 · ClinicalTrials.gov ↗ · Neurocognitive Dysfunction	Phase 3	Recruiting	2024-02	India
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma. NCT04474964 · ClinicalTrials.gov ↗ · Medulloblastoma, WNT-activated	Not applicable	Recruiting	2020-08	India
A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma NCT04250064 · ClinicalTrials.gov ↗ · DIPG Drug: Bevacizumab	Phase 2	Recruiting	2020-02	India
Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma NCT05142982 · ClinicalTrials.gov ↗ · Seminoma	Not applicable	Recruiting	2021-12	India
Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" NCT07021677 · ClinicalTrials.gov ↗ · T Acute Lymphoblastic Leukemia Drug: Daratumumab	Phase 2	Recruiting	2023-08	India
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers NCT07719946 · ClinicalTrials.gov ↗ · Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies Drug: Cyclophosphamide	Phase 2	Recruiting	2025-03	India
Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis NCT06036381 · ClinicalTrials.gov ↗ · Glioma	Observational	Recruiting	2024-02	India
Radiation Therapy in Unresectable Gall Bladder Cancer NCT06214572 · ClinicalTrials.gov ↗ · Gall Bladder Cancer Drugs: Cisplatin, Durvalumab, Nab-paclitaxel	Phase 2/3	Recruiting	2024-03	India
A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma NCT06016452 · ClinicalTrials.gov ↗ · Diffuse Glioma, Radionecrosis of Brain, High Grade Glioma	Phase 2	Recruiting	2023-11	India
Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors NCT06831461 · ClinicalTrials.gov ↗ · Primary Brain Tumors, Diffuse Glioma, Meningioma	Not applicable	Recruiting	2025-07	India
Study for Wait and Watch Suitable in Rectal Cancer NCT06252142 · ClinicalTrials.gov ↗ · Rectal Neoplasms	Observational	Recruiting	2024-04	India
Craniospinal Irradiation in Histone AlteRed Midline Glioma NCT06720727 · ClinicalTrials.gov ↗ · Glioma	Not applicable	Recruiting	2025-01	India
Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline NCT06779487 · ClinicalTrials.gov ↗ · Brain Tumors, Medulloblastoma, Glioma	Observational	Recruiting	2025-02	India
Asian Watch-and-Wait Database (AWWD) NCT06631443 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma, Rectal Cancer	Observational	Recruiting	2024-10	India
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy NCT02754115 · ClinicalTrials.gov ↗ · Colorectal Cancer, Ovarian Cancer, Peritoneal Disease	Observational	Recruiting	2016-04	India
Phase II Trial of Immunonutrition in Hepatectomy NCT07395635 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, ASA I-III Patients	Not applicable	Recruiting	2025-10	India
A Study of Chlorophyllin or Placebo With Standard Treatment for Late Radiation Induced Luminal Gastrointestinal Tract Bleeding NCT07837713 · Radiation Proctitis, Gastrointestinal Hemorrhage, Radiation Injuries Drug: Chlorophyllin, Sodium Copper Complex	Phase 3	Not yet open	2026-09	India
Surgery Vs Chemoradiation for Oropharyngeal Cancer- A Phase II/III Integrated Design Randomized Control Trial NCT05144100 · ClinicalTrials.gov ↗ · Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8	Phase 2/3	Not yet open	2021-12	India
Bladder Cancer Adjuvant Radiotherapy Trial NCT02951325 · Bladder Cancer, Urothelial Carcinoma Bladder	Phase 3	Active, closed	2016-06	India
Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer NCT02302105 · ClinicalTrials.gov ↗ · Prostate Cancer	Not applicable	Active, closed	2011-11	India
Effect of a FLUid Bolus or a Low Dose VAsopressor Infusion on Cardiovascular Collapse Among Critically Ill Adults Undergoing Tracheal Intubation. NCT05318066 · ClinicalTrials.gov ↗ · Critically Ill Adults in the ICU, Requiring Endotracheal Intubation	Not applicable	Active, closed	2022-07	India
Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial) NCT03561961 · ClinicalTrials.gov ↗ · Prostate Adenocarcinoma	Not applicable	Active, closed	2018-05	India
SCRT in TNT With or Without Chlorophyllin NCT05856305 · ClinicalTrials.gov ↗ · Rectal Neoplasms Drug: Chlorophyllin, Sodium Copper Complex	Phase 2	Active, closed	2023-07	India

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Tata Memorial Centre trials

11 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Chlorophyllin, Sodium Copper Complex2 Cisplatin2 Bevacizumab1 Cyclophosphamide1 Daratumumab1 Durvalumab1 Leflunomide1 Levetiracetam1 Nab-paclitaxel1 Oxaliplatin1 Trastuzumab1

Conditions in Tata Memorial Centre trials

69 conditions

Glioma5Diffuse Glioma3CNS Tumor2GVHD - Graft-Versus-Host Disease2Hematological Malignancy2Gall Bladder Cancer2Hematological Malignancies2Brain Tumors2Rectal Neoplasms2Artificial Intelligence (AI)1Digital Health1Malignant Neoplasm of Anal Canal1Prostate Carcinoma1Radiation Proctitis1Gastrointestinal Hemorrhage1Radiation Injuries1Bladder Cancer1Urothelial Carcinoma Bladder1Brain Tumor, Pediatric1Biliary Tract Cancer1HER2-positive Cancer1Advanced Cancer1Unresectable Biliary Tract Carcinoma1Breastcancer1

By trial register

Register	Trials	Recruiting
Clinical trials in India	42	35

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Glioma

Sponsor	Trials
Huashan Hospital	4
The First Affiliated Hospital of Zhengzhou University	4
Cerenome	2
Nuvation Bio	2
The Third Affiliated hospital of Zhejiang Chinese Medical University	2
HighField Biopharmaceuticals Corporation	1
Beijing Neurosurgical Institute	1

Sponsors with the most current trials registered for this condition.

Questions about Tata Memorial Centre trials

How many clinical trials does Tata Memorial Centre sponsor?

Tata Memorial Centre is the lead sponsor of 42 current trials on ClinicalTrials.gov in our India register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Tata Memorial Centre trials recruiting?

Yes. 35 of its 42 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Tata Memorial Centre testing?

Its current trials name 11 drugs and biologicals as interventions. The most frequent are Chlorophyllin, Sodium Copper Complex (2), Cisplatin (2), Bevacizumab (1), Cyclophosphamide (1) and Daratumumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Tata Memorial Centre clinical trials